Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ABBOTT LABORATORIES

(ABT)
  Report
Delayed Nyse  -  04:03:49 2023-01-26 pm EST
111.07 USD   +0.06%
11:51aRaymond James Adjusts Abbott Laboratories' Price Target to $123 From $109, Keeps Outperform Rating
MT
11:27aAbbott Gets FDA Nod for Spinal Cord Stimulation Device to Treat Diabetic Peripheral Neuropathy
MT
09:34aAbbott Gets Expanded FDA OK of Proclaim XR in Diabetic Peripheral Neuropathy
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Launches Panbio HIV Self Test at Retail, Increasing Access to Faster, Reliable and Discrete Testing at Home

11/21/2022 | 12:49am EST

Abbott announced it has launched a new HIV home test, the Panbio™ HIV Self Test, for over-the-counter purchase at e-commerce channels in Hong Kong, allowing users to obtain results anytime, anywhere in 15-20 minutes. The Panbio™ HIV Self Test is a newly developed rapid, fingerstick blood test for the detection of HIV-1 and HIV-2 antibodies, the two types of HIV virus that can develop into AIDS. It can recognize patients as positive 1-14 days earlier than previous second-generation tests from exposure to HIV infection.

Several peer-reviewed studies and meta-analyses have shown blood-based collection for HIV self-testing to be more accurate when compared to oral fluid (saliva) collection for rapid diagnostic tests. The number of HIV tests conducted in Hong Kong fell by 55.4% in 2020 compared with that in 2019, according to AIDS Concern Hong Kong. This was due to the closure and reduction in operational hours of testing centers due to COVID-19.

People also chose to delay testing while the COVID-19 control measures were in place. There have been significant advances around human immunodeficiency virus (HIV) detection and treatment, yet stigma and fear of a positive diagnosis are the major reasons people avoid getting tested. This innovation brings a trusted and accurate self-test to the front lines of the HIV epidemic, enabling reliable detection of HIV in the privacy of people's homes or where they live, study, socialize and work.


ę S&P Capital IQ 2022
All news about ABBOTT LABORATORIES
11:51aRaymond James Adjusts Abbott Laboratories' Price Target to $123 From $109, Keeps Outper..
MT
11:27aAbbott Gets FDA Nod for Spinal Cord Stimulation Device to Treat Diabetic Peripheral Neu..
MT
09:34aAbbott Gets Expanded FDA OK of Proclaim XR in Diabetic Peripheral Neuropathy
DJ
09:03aBernstein Adjusts Price Target on Abbott Laboratories to $132 From $125, Maintains Outp..
MT
09:01aFDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic P..
PR
08:57aJefferies Adjusts Price Target on Abbott Laboratories to $112 From $105, Maintains Hold..
MT
08:56aBarclays Adjusts Price Target on Abbott Laboratories to $125 From $122, Maintains Overw..
MT
08:55aStifel Adjusts Price Target on Abbott Laboratories to $125 From $110, Maintains Buy Rat..
MT
08:54aWolfe Research Adjusts Price Target on Abbott Laboratories to $107 From $92, Maintains ..
MT
08:54aEvercore ISI Adjusts Price Target on Abbott Laboratories to $114 From $112, Maintains O..
MT
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2022 43 227 M - -
Net income 2022 6 848 M - -
Net Debt 2022 4 567 M - -
P/E ratio 2022 28,7x
Yield 2022 1,66%
Capitalization 194 B 194 B -
EV / Sales 2022 4,58x
EV / Sales 2023 4,89x
Nbr of Employees 113 000
Free-Float 87,2%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 111,00 $
Average target price 120,97 $
Spread / Average Target 8,98%
EPS Revisions
Managers and Directors
Robert B. Ford Chairman, President, Chief Executive Officer & COO
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Glenn Fletcher Tilton Independent Director
William A. Osborn Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES2.50%193 537
MEDTRONIC PLC3.96%108 011
BECTON, DICKINSON AND COMPANY-2.96%70 152
DEXCOM, INC.-6.37%40 171
HOYA CORPORATION12.95%39 394
AMERISOURCEBERGEN CORPORATION-1.36%33 032